Katharine Yen

17.6k citations

38 papers · 5.9k indexed · 2 hit papers · h-index 22

Genetics top 0.2%
- Glioma Diagnosis and Treatment 13
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3
Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism 16
- Cancer Genomics and Diagnostics 8
Hematology top 0.5%
- Acute Myeloid Leukemia Research 19
Molecular Biology top 2%
- Epigenetics and DNA Methylation 10
- Histone Deacetylase Inhibitors Research 8
- RNA modifications and cancer 3
Oncology top 5%

Co-authors: Lenny Dang Shinsan M. Su Valeria R. Fantin Shengfang Jin Stefan Größ Craig B. Thompson Patrick S. Ward Matthew G. Vander Heiden
Cited by: Genetics Cancer Research Hematology
Journals: Nature (2 papers)Nature Medicine (1 paper)Journal of Clinical Oncology (2 papers)
Partner nations: United States France Canada

In The Last Decade

Katharine Yen

36 papers receiving 5.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Katharine Yen

Since Specialization

Citations

This map shows the geographic impact of Katharine Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katharine Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katharine Yen more than expected).

Fields of papers citing papers by Katharine Yen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katharine Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katharine Yen. The network helps show where Katharine Yen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Katharine Yen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katharine Yen Line = papers co-authored together Katharine Yen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 903: AURIGIN: A comprehensive single-cell OMICs atlas of human development and an AI/ML framework to classify and identify the drivers of tumor plasticity and altered cellular state Cancer Research ·Joseph DeBartolo,Henry S. Wilson,Kimberly Straley,Maulasri Bhatta,Sambad Sharma,Sara Sinicropi-Yao,James Neef,Betty Chan,Andrew J. McRiner,Mark Bittinger,Laura Antipov,Katharine Yen,Thomas G. Graeber,David S. Millan	2024	0
2	AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model Blood ·Hélène Duparc,James Neef,Janany Kandiah,Maulasri Bhatta,Agathe L. Chédeville,Joe DeBartolo,Sara Sinicropi-Yao,Betty Chan,Alex Constan,Christophe Marzac,Jean‐Baptiste Micol,Laura Antipov,Stéphane de Botton,Katharine Yen,David S. Millan,Iléana Antony‐Debré,Kimberly Straley	2024	1
3	Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation Nature Medicine ·Birgit Geoerger,Manuel Schiff,Virginie Penard‐Lacronique,Niklas Darín,Selim-Maria Saad,Clarisse Duchon,Antonin Lamazière,Aurore Desmons,Clément Pontoizeau,Pablo Berlanga,Stéphane Ducassou,Katharine Yen,Michael Su,David P. Schenkein,Chris Ottolenghi,Stéphane de Botton	2023	5
4	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia Cancer Discovery ·Alan H. Shih,Cem Meydan,Kaitlyn Shank,Francine E. Garrett-Bakelman,Patrick S. Ward,Andrew M. Intlekofer,Abbas Nazir,Eytan M. Stein,Kristina M. Knapp,Jacob L. Glass,Jeremy Travins,Kim Straley,Camelia Gliser,Christopher E. Mason,Katharine Yen,Craig B. Thompson,Ari Melnick,Ross L. Levine	2017	71
5	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Blood ·Michael Amatangelo,Lynn Quek,Alan H. Shih,Eytan M. Stein,Mikhail Roshal,Muriel D. David,Benoît Marteyn,Noushin Farnoud,Stéphane de Botton,Olivier Bernard,Bin Wu,Katharine Yen,Martin S. Tallman,Elli Papaemmanuil,Virginie Penard‐Lacronique,Anjan Thakurta,Paresh Vyas,Ross L. Levine	2017	249
6	A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML Leukemia ·Lev M. Kats,Stephin J. Vervoort,Rachel M. Cole,Amy J. Rogers,Gareth P. Gregory,Eva Vidacs,Jason Li,Raj Nagaraja,Katharine Yen,Ricky W. Johnstone	2017	23
7	IDH mutations in cancer and progress toward development of targeted therapeuticsbreakdown → Annals of Oncology ·Lenny Dang,Katharine Yen,Eyal C. Attar	2016	363
8	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer Clinical Cancer Research ·Owen Clark,Katharine Yen,Ingo K. Mellinghoff	2016	147
9	Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance Cell stem cell ·Lev M. Kats,Markus Reschke,Riccardo Taulli,Olga Pozdnyakova,Kerri Burgess,Parul Bhargava,Kimberly Straley,Rahul Karnik,Alexander Meissner,Donald Small,Shinsan M. Su,Katharine Yen,Jiangwen Zhang,Pier Paolo Pandolfi	2014	146
10	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo Blood ·Erica Hansen,Cyril Quivoron,Kim Straley,René M. Lemieux,Janeta Popovici-Müller,Hossein Sadrzadeh,Amir T. Fathi,Camelia Gliser,Muriel D. David,Véronique Saada,Jean‐Baptiste Micol,Olivier Bernard,Marion Dorsch,Hua Yang,Michael Su,Sam Agresta,Stéphane de Botton,Virginie Penard‐Lacronique,Katharine Yen	2014	40
11	AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies Blood ·Eytan M. Stein,Jessica K. Altman,Robert H. Collins,Daniel J. DeAngelo,Amir T. Fathi,Ian W. Flinn,Arthur E. Frankel,Ross L. Levine,Bruno C. Medeiros,Manish R. Patel,Daniel A. Pollyea,Gail J. Roboz,Richard M. Stone,Ronan Swords,Martin S. Tallman,Sam Agresta,Bin Fan,Hua Yang,Katharine Yen,Stéphane de Botton	2014	68
12	Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate The Oncologist ·Amir T. Fathi,Hossein Sadrzadeh,Amy Comander,Michaela J. Higgins,Aditya Bardia,Ashley Perry,Meghan Burke,Regina Silver,Christina R. Matulis,Kimberly Straley,Katharine Yen,Sam Agresta,Hyeryun Kim,David P. Schenkein,Darrell R. Borger	2014	59
13	IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition Blood ·Andrew Kernytsky,Fang Wang,Erica Hansen,Stefanie S. Schalm,Kimberly Straley,Camelia Gliser,Hua Yang,Jeremy Travins,Stuart Murray,Marion Dorsch,Sam Agresta,David P. Schenkein,Scott A. Biller,Shinsan M. Su,Wei Liu,Katharine Yen	2014	128
14	IDH1 Mutant Inhibitor Induces Cellular Differentiation and Offers a Combination Benefit With Ara-C In a Primary Human Idh1 Mutant AML Xenograft Model Blood ·Katharine Yen,René M. Lemieux,Janeta Popovici-Müller,Yue Chen,Hua Yang,Kim Straley,Sung Choe,Marion Dorsch,Samuel Agresta,David P. Schenkein,Scott A. Biller,Michael Su,Fang Wang	2013	13
15	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop Neuro-Oncology ·Jason T. Huse,M. Z. Wallace,Kenneth Aldape,Mitchel S. Berger,Chetan Bettegowda,Daniel J. Brat,Daniel P. Cahill,Timothy F. Cloughesy,Daphne A. Haas‐Kogan,Marco A. Marra,C. Ryan Miller,Sarah J. Nelson,Sofie R. Salama,Riccardo Soffietti,Patrick Y. Wen,Stephen Yip,Katharine Yen,J Costello,Susan M. Chang	2013	23
16	Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo ACS Medicinal Chemistry Letters ·Janeta Popovici-Müller,Jeffrey O. Saunders,Francesco G. Salituro,Jeremy Travins,Shunqi Yan,Fang Zhao,Stefan Größ,Lenny Dang,Katharine Yen,Hua Yang,Kimberly Straley,Shengfang Jin,Kaiko Kunii,Valeria R. Fantin,Shunan Zhang,Qiongqun Pan,Derek Shi,Scott A. Biller,Shinsan M. Su	2012	160
17	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function Genes & Development ·Masato Sasaki,Christiane B. Knobbe‐Thomsen,Momoe Itsumi,Andrew Elia,Isaac S. Harris,Iok In Christine Chio,Rob A. Cairns,Susan McCracken,Andrew Wakeham,Jillian Haight,Annick You Ten,Bryan E. Snow,Takeshi Ueda,Satoshi Inoue,Kazuo Yamamoto,Myunggon Ko,Anjana Rao,Katharine Yen,Shinsan M. Su,Tak W. Mak	2012	224
18	Cancer-associated IDH mutations: biomarker and therapeutic opportunities Oncogene ·Katharine Yen,M. Bittinger,Shinsan M. Su,Valeria R. Fantin	2010	227
19	Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Cancer Research ·Valeria R. Fantin,Lenny Dang,David W. White,Stefan Größ,Mark Bittinger,Edward M. Driggers,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Katharine Yen,Patrick S. Ward,Robert M. Prins,Linda M. Liau,Bryson D. Bennett,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	2010	4
20	Cancer-associated IDH1 mutations produce 2-hydroxyglutaratebreakdown → Nature ·Lenny Dang,David W. White,Stefan Größ,Bryson D. Bennett,Mark Bittinger,Edward M. Driggers,Valeria R. Fantin,Hyun Gyung Jang,Shengfang Jin,Marie C. Keenan,Kevin M. Marks,Robert M. Prins,Patrick S. Ward,Katharine Yen,Linda M. Liau,Joshua D. Rabinowitz,Lewis C. Cantley,Craig B. Thompson,Matthew G. Vander Heiden,Shinsan M. Su	2009	3067

About Katharine Yen

Katharine Yen is a scholar working on Hematology, Genetics and Cancer Research, having authored 38 papers that have together received 5.9k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (19 papers), Cancer, Hypoxia, and Metabolism (16 papers), Glioma Diagnosis and Treatment (13 papers), Epigenetics and DNA Methylation (10 papers), Histone Deacetylase Inhibitors Research (8 papers), Cancer Genomics and Diagnostics (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Genetics (2.1k citations), Cancer Research (2.8k citations) and Hematology (1.2k citations). Katharine Yen has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Lenny Dang, Shinsan M. Su, Valeria R. Fantin, Shengfang Jin, Stefan Größ, Craig B. Thompson, Patrick S. Ward, Matthew G. Vander Heiden, Marie C. Keenan and Joshua D. Rabinowitz. Their work appears in journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact